- Under most state pharmacy laws, what must the pharmacist do if the label on a prescription being filled has illegible information due to a printer malfunction?
Answer: The pharmacist must reprint a legible label before dispensing the medication.
A legible label is a fundamental labeling requirement. Dispensing with a partially illegible label is a violation; the label must be reprinted before dispensing. B correctly identifies this obligation. A is incorrect because patients should not have to ask questions to decipher required label information. C is incorrect because a handwritten correction on a partially illegible label may not satisfy legibility requirements. D is incorrect because verbal explanation does not substitute for a legible label that the patient needs for ongoing medication management.
- Under state pharmacy law, what is generally required when a pharmacist dispenses a different manufacturer's generic drug than the one originally dispensed at the last refill?
Answer: The label must include the new manufacturer's name, and the patient must be informed of the change.
The label must reflect the actual product dispensed. When a different generic manufacturer is used, the patient should be counseled about appearance differences and confirmation of therapeutic equivalence. Some states require disclosure of generic manufacturer changes. B correctly identifies these obligations. A is incorrect because the label must be updated and patient counseling is warranted. C is incorrect because prescriber authorization is not required for generic manufacturer substitution among therapeutically equivalent products. D is incorrect because the label itself must reflect the actual dispensed product.
- Under FDA regulations, oral contraceptives require a patient package insert (PPI) to be dispensed with each fill. Which of the following best describes this requirement?
Answer: The PPI must be dispensed with every fill of oral contraceptives, including refills.
FDA regulations require the oral contraceptive patient package insert to be dispensed at each fill, including refills. D correctly identifies this ongoing requirement. A is incorrect because the PPI must accompany each fill, not only the first. B is incorrect because PPI dispensing is mandatory, not conditioned on prescriber request. C is incorrect because PPI provision is mandatory rather than optional.
- A patient who speaks only Spanish picks up a prescription. The pharmacy's standard labels are printed only in English. Under most state laws and guidance, which of the following best applies?
Answer: The pharmacy should provide translated label directions or a supplemental translation when reasonably possible.
While federal law does not universally mandate non-English labels, multiple states and CMS guidance encourage or require translated labels for patients who do not read English, to ensure safe medication use. Reasonable efforts should be made. D correctly identifies this obligation. A is incorrect because federal minimums do not preclude stronger state requirements and good pharmacy practice. B is incorrect because refusing to dispense is not the required response. C is incorrect because verbal explanation alone is insufficient if the patient must use the label for medication management.
- A compounding pharmacy prepares a patient-specific sterile preparation. Under USP Chapter 797 and applicable state law, what information must appear on the label of this compounded preparation?
Answer: Patient name, drug name, strength, beyond-use date, and storage requirements.
Compounded sterile preparation labels must be comprehensive: patient name, prescriber, active ingredients/strength, quantity/volume, pharmacy identity, directions, route, beyond-use date, storage requirements, preparation date, lot number, and compounder identity. A correctly identifies these comprehensive requirements. B is incorrect because drug name and beyond-use date alone are far below required compounded preparation labeling. C is incorrect because patient name and preparation date alone are insufficient. D is incorrect because pharmacy name and initials alone are far below required labeling.
- Under FDA regulations, auxiliary warning labels such as 'Do not take with grapefruit juice' or 'May cause drowsiness -- use caution when driving' serve which of the following purposes?
Answer: Auxiliary labels provide critical safety information about drug interactions and potential side effects.
Auxiliary warning labels provide additional safety information -- drug interactions, precautions, side effect warnings -- supplementing the primary label to support safe medication use. B correctly identifies this purpose. A is incorrect because auxiliary labels serve a defined patient safety function and may be required by state law for certain drug categories. C is incorrect because DEA regulations do not specifically mandate auxiliary labels for all controlled substances. D is incorrect because auxiliary labels address drug-specific safety information, not patient allergy status.
- A pharmacist dispenses a 90-day supply of a statin for a mail-order patient. Under federal labeling requirements, which of the following must appear on the dispensing label?
Answer: Pharmacy name and address, prescription number, patient name, prescriber name, date, and directions.
Under 21 CFR 201.100, the federal dispensing label requirements for prescription drugs include the pharmacy name and address, prescription number, patient name and address, prescriber name, date dispensed, and directions for use. States commonly require additional elements such as drug name and strength, quantity, refills remaining, and pharmacist identification. A correctly identifies the federal baseline and notes that state law adds further elements. B is incorrect because prior counseling does not relieve the label of required elements. C is incorrect because insurance information is not a required label element. D is incorrect because a website address alone is not a substitute for required label information.
- Under 21 CFR 201.100, which of the following is required on the label of a prescription drug dispensed to a patient?
Answer: The pharmacy's name and address, prescription serial number, and usage directions.
21 CFR 201.100 requires the dispensing pharmacy's name and address, prescription serial number, fill date, prescriber's name, patient's name, and directions for use with cautionary statements as directed by the prescriber. A correctly identifies these federal label requirements. B is incorrect because drug name and dosage form alone are insufficient. C is incorrect because insurance ID is not a required label element. D is incorrect because date and initials alone fall far below federal requirements.
- Under most state pharmacy laws, when a pharmacist transfers a prescription between pharmacies, what labeling obligations apply at the receiving pharmacy that fills the transferred prescription?
Answer: The receiving pharmacy must create a new label meeting all legal requirements, identifying itself as the dispensing pharmacy.
When a pharmacy dispenses a transferred prescription, it is a new dispensing event. The receiving pharmacy must generate a new, complete label meeting all labeling requirements and identifying itself as the dispensing pharmacy. D correctly identifies this requirement. A is incorrect because the original pharmacy's label is not appropriate for the receiving pharmacy's dispensing. B is incorrect because simply adding the receiving pharmacy's name is insufficient for a complete compliant label. C is incorrect because the transferred prescription requires a new dispensing label.
- Under most state pharmacy laws, which of the following auxiliary statements is required to appear on the dispensing label for a Schedule II or III controlled substance?
Answer: Caution: Federal law prohibits transfer to anyone other than the prescribed patient.
Federal law (21 CFR 290.5) requires the transfer warning on labels for Schedule II through V controlled substance dispensing: 'Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.' C correctly identifies this required statement. A is incorrect because a schedule sticker is not the federally required auxiliary statement for controlled substance dispensing labels. B is incorrect because prescription-only status is communicated elsewhere; the specific transfer warning is the required auxiliary statement. D is incorrect because the pharmacist's personal contact information is not a required label element.
- A pharmacy is dispensing a medication that has an FDA-required Medication Guide. Under FDA regulations, which of the following must the pharmacy do at each dispensing?
Answer: Provide the Medication Guide with every dispensing, including refills.
FDA regulations require Medication Guides to be provided with each dispensing of the medication, including each refill. C correctly identifies this ongoing requirement. A is incorrect because the Medication Guide must be provided at each fill, not only the first. B is incorrect because dispensing is proactive and mandatory, not contingent on patient request. D is incorrect because placing the Medication Guide on file does not satisfy the requirement; it must be provided to the patient at each fill.
- Under USP Chapter 795 and state laws, what beyond-use date (BUD) labeling is required for non-sterile compounded preparations?
Answer: The BUD must be labeled based on USP 795 guidelines and stability data for non-sterile compounded preparations.
Non-sterile compounded preparation labels must include a prominently displayed BUD determined per USP Chapter 795 guidelines and stability data. C correctly identifies this requirement. A is incorrect because BUD labeling is required, not optional. B is incorrect because the BUD is not simply the longest ingredient date; formulation-specific stability analysis governs. D is incorrect because a universal 14-day BUD is not the USP 795 standard; BUDs are determined based on formulation type and stability data.
- Under most state laws, a pharmacy dispenses a brand-name product when a generic is available and substitution is permitted. The prescriber did not indicate 'brand medically necessary.' Which of the following best describes the labeling obligation?
Answer: The label must indicate the brand-name product was dispensed if a generic was available.
The label must accurately reflect the actual dispensed product. Some states require notation when a brand is dispensed and generic substitution was available. C correctly identifies this requirement. A is partially correct but C is more precise about the state notation requirement. B is incorrect because label accuracy is required, not pharmacist discretion. D is incorrect because the generic name is not universally required when a brand-name product was actually dispensed.
- Under the FDCA, which of the following best describes the concept of adequate directions for use on a prescription drug label?
Answer: Adequate directions for use means instructions enabling safe use by a layperson.
The FDCA defines adequate directions for use as those written so a layperson can use the drug safely: dose, frequency, duration, route, and special instructions in clear, understandable language. C correctly identifies this standard. A is incorrect because drug name and category alone are not adequate directions. B is incorrect because language accessibility for the patient, not pharmacist preference, governs. D is incorrect because prescriber verbatim instructions may themselves be inadequate if not clear enough for layperson use.
- A patient picks up a prescription and notices that the label lists the wrong patient name -- it has a similar name but is actually another patient's prescription. Under labeling requirements, which of the following is the pharmacist's obligation?
Answer: The pharmacist must retrieve the prescription, correct the label, and ensure the correct patient receives the medication.
A mislabeled prescription with the wrong patient name is a dispensing and labeling error requiring immediate retrieval, correction, documentation, and assessment of whether the incorrectly named patient may have received the wrong prescription. A correctly identifies this comprehensive response. B is incorrect because a sticker is not adequate correction of a mislabeled prescription; the label must be reprinted correctly. C is incorrect because patient name is a required label element and the patient cannot be expected to guess from drug name. D is incorrect because apology and notation alone without correction and investigation do not satisfy labeling and error management obligations.
- A pharmacy changes computer systems and the new system prints labels without the prescriber's name. Prescriptions are being dispensed with this incomplete label. Which of the following best analyzes the compliance concern?
Answer: The prescriber's name is required on labels by law; dispensing without it is non-compliant and must be corrected immediately.
Prescriber name is a required element under 21 CFR 201.100 and most state pharmacy laws. Labels without this element are non-compliant and must be corrected before dispensing continues. B correctly identifies this compliance concern. A is incorrect because prescriber identification is a legally required label element. C is incorrect because a bag sticker is not a substitute for the required label element. D is incorrect because prescriber name is required on all prescription dispensing labels, not only controlled substances.
- A pharmacy's computer system automatically truncates long drug names on the label. A drug name is shortened in a way that could be confused with another medication. Which of the following best applies?
Answer: Truncation causing confusion is a labeling error; drug names must be clear and unambiguous.
Drug name clarity is essential for patient safety. Truncations that create potential confusion with another medication are labeling deficiencies that must be corrected. C correctly identifies this patient safety and compliance concern. A is incorrect because length preferences do not justify confusing truncations. B is incorrect because NDC accuracy is separate from the drug name clarity required for the patient-facing label. D is incorrect because pharmacist initials do not cure a patient-facing labeling deficiency.
- Under 21 CFR 290.5, which schedules of controlled substances require the transfer warning label 'Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed'?
Answer: Schedules II, III, and IV.
21 CFR 290.5 requires the transfer warning label -- 'Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed' -- on dispensing labels for prescription drug products containing Schedule II, III, and IV controlled substances. B correctly identifies this scope. A is incorrect because Schedule I substances are not lawfully dispensed by retail pharmacies and are not the subject of this retail labeling requirement. C is incorrect because the requirement extends beyond Schedule II to Schedules III and IV as well. D is incorrect because it omits Schedule II, which is included in the requirement.
- A patient's prescription reads 'take one tablet twice daily' and the pharmacist prints this exactly on the label. The patient is a child and the prescriber intended a weight-based dose that was communicated verbally but not written. Which of the following best applies to this labeling situation?
Answer: The pharmacist must verify and document the correct pediatric dose with the prescriber before dispensing.
The label must reflect the authorized dose, and the pharmacist has a duty to clarify a potential pediatric dosing discrepancy. For a non-controlled prescription, the pharmacist may contact the prescriber, receive a verbal clarification or change, document it in the prescription record, and dispense with a corrected label. A verbal prescriber-authorized change that is properly documented satisfies the prescription and labeling requirement. A correctly identifies this process. B is incorrect because the pharmacist may not add a weight-based dose to the label solely on the basis of an undocumented verbal statement from a non-prescriber source; the prescriber must authorize the change. C is incorrect because a potential dosing discrepancy for a pediatric patient requires clarification, not silent dispensing based on the original written directions. D is incorrect because adding a weight note does not resolve the dose discrepancy; a clarified authorized dose from the prescriber is required.
- A pharmacist receives a prescription for amoxicillin with directions that simply read 'take as directed.' Under labeling requirements, which of the following best applies?
Answer: The pharmacist must obtain specific dosing instructions from the prescriber before dispensing to ensure proper labeling.
Vague directions like 'take as directed' do not satisfy the labeling requirement for adequate directions for use. The pharmacist should contact the prescriber for specific dosing information. B correctly identifies this obligation. A is incorrect because inadequate prescriber directions do not excuse inadequate labeling. C is incorrect because the label itself must contain adequate directions regardless of verbal instructions at pick-up. D is incorrect because the pharmacist cannot unilaterally supply specific dosing without prescriber authorization.
